ArticleDrugs & aging2026
Prevalence of Beers Criteria Potentially Inappropriate Medication Use and Associated Factors among Three US Studies.
Chris M Gillette, Andrea M Anderson, Courtney J Perry, Dave M Reboussin, Pamela L Lutsey, Lynne E Wagenknecht, Michael P Bancks
Abstract read
In one paragraphArticle in Drugs & aging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
7 authors.
Chris M GilletteDepartment of PA Studies, Wake Forest University School of Medicine, Winston-Salem, USA.
Andrea M AndersonDepartment of Biostatistics and Data Science, Wake Forest University School of Medicine, Winston-Salem, USA.
Courtney J PerryDepartment of PA Studies, Wake Forest University School of Medicine, Winston-Salem, USA.
Dave M ReboussinDepartment of Biostatistics and Data Science, Wake Forest University School of Medicine, Winston-Salem, USA.
Pamela L LutseyDivision of Epidemiology & Community Health, University of Minnesota School of Public Health, Minneapolis, MN, USA.
Lynne E WagenknechtDepartment of Epidemiology and Prevention, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC, 27157, USA.
Michael P BancksDepartment of Epidemiology and Prevention, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC, 27157, USA. michael.bancks@wfusm.edu.ORCID 0000-0003-3694-6060 Funding
ARIC Neurocognitive Study (ARIC-NCS) Renewal 2023-2028U01HL096812 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI JOSEF CORESH, THOMAS H MOSLEY · 2010 to 2026
$65.7MTask Area A Core Study Operations.Task Area A shall encompass annual follow-up of cohort members, clinical endpoints ascertainment, study coordination activities, maintenance of the database and biosp75N92020D00001 · NHLBI · UNIVERSITY OF WASHINGTON · PI MCCLELLAND, ROBYN LEAGH · 2020 to 2025
$17.2MTHE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY - COORDINATING CENTER - TASK AREA B.2 AND B.375N92022D00001 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI COUPER, DAVID · 2022 to 2025
$13.7MARIC Neurocognitive Study (ARIC-NCS) Renewal UNC 4 of 5U01HL096899 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI COUPER, DAVID J · 2010 to 2018
$7.5MARIC Neurocognitive Study (ARIC-NCS)U01HL096902 · NHLBI · UNIVERSITY OF MINNESOTA · PI LUTSEY, PAMELA L. · 2010 to 2018
$7.4MARIC Neurocognitive Study (ARIC-NCS) Renewal 4 of 5U01HL096814 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI HUGHES, TIMOTHY M., WAGENKNECHT, LYNNE E · 2010 to 2018
$6.5MTHE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY - FIELD CENTER - TASK ORDER 01, TASK AREA A75N92022D00003 · NHLBI · UNIVERSITY OF MINNESOTA · PI LUTSEY, PAMELA L. · 2022 to 2025
$5.1MTask Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00005 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WATSON, KAROL E · 2020 to 2025
$5.1MTHE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY - FIELD CENTER - TASK ORDER 01, TASK AREA A75N92022D00005 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI WAGENKNECHT, LYNNE E · 2022 to 2025
$5.0MTHE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY - FIELD CENTER - TASK ORDER 01, TASK AREA A75N92022D00004 · NHLBI · UNIVERSITY OF MISSISSIPPI MED CTR · PI WINDHAM, BEVERLY GWEN · 2022 to 2025
$4.8MTHE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY - FIELD CENTER - TASK ORDER 01, TASK AREA A75N92022D00002 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI ARGANI, PEDRAM · 2022 to 2025
$4.7MTO EXERCISE OPTION PERIOD ONE (1) FOR TASK AREA A - MESA CORE OPERATIONS, FIELD CENTER.75N92020D00004 · NHLBI · NORTHWESTERN UNIVERSITY · PI SIEGEL, JONATHAN H · 2020 to 2025
$4.5MNHLBI NIH HHS K24 HL159246NIA NIH HHS R03AG077368NIH HHS 75N92020D00001NIH HHS 75N92020D00002NIH HHS 75N92020D00003NIH HHS 75N92020D00004NIH HHS 75N92020D00005NIH HHS 75N92020D00006NIH HHS 75N92020D00007NIH HHS 75N92022D00001NIH HHS 75N92022D00002NIH HHS 75N92022D00003NIH HHS 75N92022D00004NIH HHS 75N92022D00005NIH HHS DK56990NIH HHS DK56992.NIH HHS DK57002NIH HHS DK57008NIH HHS DK57078NIH HHS DK57131NIH HHS DK57135NIH HHS DK57136NIH HHS DK57149NIH HHS DK57151NIH HHS DK57154NIH HHS DK57171NIH HHS DK57177NIH HHS DK57178NIH HHS DK57182NIH HHS DK57219NIH HHS HHSN268201500003INIH HHS N01-HC-95159NIH HHS N01-HC-95160NIH HHS N01-HC-95161NIH HHS N01-HC-95162NIH HHS N01-HC-95163NIH HHS N01-HC-95164NIH HHS N01-HC-95165NIH HHS N01-HC-95166NIH HHS N01-HC-95167NIH HHS N01-HC-95168NIH HHS N01-HC-95169NIH HHS U01HL096812NIH HHS U01HL096814NIH HHS U01HL096899NIH HHS U01HL096902NIH HHS U01HL096917.NIH HHS UL1-TR-000040NIH HHS UL1-TR-001079NIH HHS UL1-TR-001420
6 · The paper itselfAbstract
backgroundThe aim of this study was to assess the prevalence of potentially inappropriate medication (PIM) use among adults ≥ 65 years, overall and for population subgroups, and factors associated with prevalent PIM use.
methodsParticipant and medications data from the Atherosclerosis Risk in Communities (ARIC), Multi-ethnic Study of Atherosclerosis (MESA), and Action for Health in Diabetes (Look AHEAD) were used. The total number of individuals contributing to analysis was 9439 for ARIC, 5223 for MESA, and 3771 for Look AHEAD. Participants' medication data were collected at study exams with medication inventories. Prevalence of any PIM use (yes/no), total number of PIMs used, and the major drug classes of PIMs used within a cohort were identified using Beers Criteria closest to the time of study exam (1997 onward) for all participants aged 65 years or older. Multivariable adjusted logistic regression was used to assess demographic and clinical factors associated with prevalence of any Beers Criteria PIM at the first exam after turning 65 years of age, separately for each cohort.
resultsThe prevalence of PIM use at the first exam at ≥ 65 years was 67% in ARIC, 51% in MESA, and 70% in Look AHEAD. The most prevalently used PIM classes across cohorts were non-aspirin pain medications, proton-pump inhibitors, and sulfonylureas. Higher body mass index and diabetes were consistently associated with greater odds of PIM use across cohorts.
conclusionsUse of potentially inappropriate prescription and nonprescription medications was highly prevalent across three diverse cohorts and highlights the need for clinicians and pharmacists to review patient medication lists and optimize management of medications.
Indexed as
Inappropriate PrescribingPotentially Inappropriate Medication ListAgedCohort StudiesFemaleHumansMalePrevalenceRisk FactorsUnited States
Identifiers
PMID41661525
PMCPMC12995985
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390